Squarepoint’s Aardvark Therapeutics AARD Stock Holding History

Squarepoint’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,186	Closed	-$107K	–	5208
2025 Q1	$107K	Buy	+14,186	New	+$159K	﹤0.01%	4203

Other funds holding AARD

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's AARD Position: Q2 2025 in Review

Squarepoint sold out of Aardvark Therapeutics (AARD) in Q2 2025, closing a stake of 14,186 shares — an estimated $107K sold.

Squarepoint first reported a position in AARD in Q1 2025 and held it in 1 quarter. The position peaked at $107K in Q1 2025. 35 funds tracked by Wall St. Rank hold AARD as of Q2 2025.

Squarepoint reported no remaining Aardvark Therapeutics position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 14,186 Aardvark Therapeutics shares in Q2 2025, an estimated $107K.
Squarepoint first reported a position in Aardvark Therapeutics in Q1 2025 and held it in 1 quarter.
Squarepoint's Aardvark Therapeutics position peaked at $107K in Q1 2025.
35 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.